Eli Lilly and Co
(NYSE:LLY)
$
806.06
-0.08 (-0.01%)
Market Cap: 765.21 Bil
Enterprise Value: 792.88 Bil
PE Ratio: 87.14
PB Ratio: 50.92
GF Score: 87/100 
Eli Lilly and Co at UBS Global Healthcare Conference Transcript
May 21, 2019 / 01:30PM GMT
Release Date Price:
$116.58
(+0.30%)
Navin Cyriac Jacob
UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic
(technical difficulty)
to UBS Global Healthcare conference Day 2. My name is Navin Jacob. I'm the senior analyst for global pharma and for smid-cap biotech. I'm happy to have here with me, Christi Shaw, SVP and President of Lilly Biosciences. Thank you for joining us, Christi.
Christi Shaw
Eli Lilly and Company - Senior VP & President of Lilly Bio-Medicines
Absolutely. Hello everyone.
Questions & Answers
Navin Cyriac Jacob
UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic
So Christi, you're responsible for a portfolio that includes pain and inflammation. Those spaces, particularly inflammation, like diabetes, is a space that is highly rebated. The administration has a proposal to change the rebate rule and -- or has a rebate rule proposed. Wondering how you think about the potential
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers